# Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer

> **NCT05072600** · PHASE2 · RECRUITING · sponsor: **Peking University First Hospital** · enrollment: 54 (estimated)

## Conditions studied

- Bladder Cancer
- Bladder Neoplasms
- Bladder Tumors
- Urinary Bladder Cancer
- Neoplasms, Bladder

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05072600
- **Lead sponsor:** Peking University First Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-07
- **Primary completion:** 2024-12-07
- **Final completion:** 2029-11-01
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2022-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05072600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05072600, "Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05072600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*